This study examined the use of prophylactic Haloperidol in ICU patients at high risk of delirium. While it is often a treatment agent used when non-pharmacological approaches to delirium fail, this study confirms that prophylactic use exerts no beneficial effect on long-term quality of life in ICU survivors.
The REDUCE study previously showed that neither does it reduce the incidence or duration of delirium.
“The factors age, medical, and trauma admission, baseline quality of life, risk for delirium, and the number of sedation-induced coma days are associated with the decline in long-term outcome parameters.”
And a major message is “Every additional day of sedation-induced coma is associated with further decline of long-term physical and mental function”.